ALZA GAINS ON CATAPRES TTS "APPROVABLE" ANNOUNCEMENT; INDEX DECLINES
Executive Summary
Robins (up 1-1/2 to 17) and Alza (up 1-3/8 to 18-1/4) were the only point-plus gainers among listed stocks on the Pharmaceutical Component of the "F-D-C" Weekly Index for the week ended Sept. 7. Alza advanced on the announcement that Boehringer Ingelheim's Catapres TSS, a once-weekly forumulation of clonidine using Alza's controlled-release drug delivery technology, had reached the "approvable" stage at FDA. For the week, both Pharmaceutical and Diversified Components slumped 1.3%, pushing the Composite down 1.2%, while the Dow dipped 1.4%. Chart omitted.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: